DOCSLIB.ORG

Customized Medications for Anti-Aging

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Customized Medications for Anti-Aging Customized Medications for Anti-Aging Topical Treatment of Aging Skin Therapy for wrinkles and photoaging of the skin is an area of ongoing research. At ClearSpring Pharmacy, cosmeceuticals can be customized to treat aging skin. Optimal formulation and our use of patented bases will maximize the benefits while minimizing any potential side effects of these therapies. Skin aging includes intrinsic and extrinsic processes, with cell damage caused by metabolic processes, free radicals and cosmic irradiation. Topical and oral administration of antioxidants such as vitamins E and C, coenzyme Q10, alpha- lipoic acid and glutathione enhance antiaging effect. Other antioxidants such as green tea, dehydroepiandrosterone, melatonin, selenium and resveratrol, have Natural Therapies & Prescriptions That Enhance Life. TM also antiaging and anti-inflammatory effects. Topical bleaching agents such as hydroquinone, kojic acid and azelaic acid can reduce signs of aging. Studies confirm the efficacy of these topical agents in combination with superficial and/ or medium depth or deep peeling agents for photodamaged skin treatment. www.clearspringrx.com Based on individual patient needs, preparations may also contain retinoids, hydroxy acids, bleaching agents, moisturizers, and sunscreens. CHERRY CREEK Coll Antropol. 2010 Sep;34(3):1145-53. 201 UNIVERSITY BOULEVARD, #105 Estrogen Therapy to Prevent or Reverse Skin Aging DENVER, CO 80206 T 303.333.2010 Declining estrogen levels are associated with a variety of cutaneous changes, many of which can be reversed or improved by topical or systemic estrogen F 303.333.2208 supplementation. Studies of postmenopausal women indicate that estrogen deprivation is associated with declining dermal collagen content, diminished elasticity and skin strength, loss of moisture in the skin, epidermal thinning, atrophy, fine wrinkling, and impaired wound healing. Keratinocytes, Langerhans’ cells, LITTLETON melanocytes, sebaceous glands, collagen content and the synthesis of hyaluronic 8031 SOUTHPARK CIRCLE, SUITE B acid are under hormonal influence. Estrogen may attenuate inflammation in LITTLETON, CO 80120 psoriatic lesions. Alone or together with progesterone, estrogen prevents or reverses skin atrophy, dryness and wrinkles associated with chronological or photo- T 303.707.1500 aging. Estrogen and progesterone stimulate proliferation of keratinocytes while F 303.707.1717 estrogen suppresses apoptosis and thus prevents epidermal atrophy. Estrogen maintains skin moisture by increasing acid mucopolysaccharide or hyaluronic acid levels in the dermis, and accelerates cutaneous wound healing. Low estrogen levels that accompany menopause exacerbate the deleterious effects of both intrinsic and environmental aging. Estrogens clearly have a key role in skin aging homeostasis as evidenced by the accelerated decline in skin appearance seen in the perimenopausal years. The effects of topical application of 0.01% estradiol and 0.3% estriol compounds were compared in 59 preclimacteric women with skin aging symptoms. After treatment for 6 months, elasticity and firmness of the skin had markedly improved and wrinkle depth and pore sizes had decreased by 61 to 100% in both groups. Systemic estrogen levels did not increase and no systemic hormonal side effects were noted. At Yale University School of Medicine, the effects of long-term hormone replacement therapy (HRT) on skin rigidity and wrinkling at 11 facial locations was assessed using the Lemperle scale by a plastic surgeon who was blinded to HRT use. Skin rigidity at the cheek and forehead was measured with a durometer. Demographics including age, race, sun exposure, sunscreen use, tobacco use, and skin type were similar. Rigidity was significantly decreased in HRT users compared to nonusers at both the cheek and forehead. Average wrinkle scores were lower in hormone users than in nonhormone users. The study concluded that long- term postmenopausal HRT users have more elastic skin and less severe wrinkling than women who never used HRT, suggesting that hormone therapy may have cosmetic benefits. In another study, the dermal collagen of 15 postmenopausal women who had received systemic estrogen replacement was analyzed before and after using a topical 0.01% estrogen treatment. Epithelial and dermal thickness improved after topical estrogen therapy. Facial skin collagen significantly increased after 16 weeks of treatment. Systemic estrogen levels did not significantly increase after topical therapy. A randomized, double-blind, estrogen-controlled trial evaluated the effects of topical estrogen and isoflavones on facial skin of postmenopausal women, who received either 17-betaestradiol 0.01% or isoflavones 40% (genistein 4%). Skin biopsies were performed on each patient before and after the treatment. After 24 weeks of treatment, the estradiol group had significant improvement compared to the isoflavone group and to the baseline measurements: epidermal thickness (a 75% increase in the estrogen group and 20% in the isoflavone group), number of dermal papillae (a rise of 125% with estrogen, no significant gain with isoflavones), fibroblasts (a 123% accretion with estradiol, no significant gain with isoflavones), and vessels (a 77% increase with estrogen and 36% with isoflavones). This data suggests that treatment with topical estrogens may have a stronger effect on histomorphometrical parameters than isoflavones. Exp Dermatol. 2004;13 Suppl 4:36-40 Int J Dermatol. 1996 Sep;35(9):669-74. Exp Dermatol. 2006 Feb;15(2):83-94 Eur J Obstet Gynecol Reprod Biol. 2006 Jun 22 J Am Acad Dermatol. 2005 Oct;53(4):555-68; quiz 569-72 Fertil Steril. 2005 Aug;84(2):285-8 Am J Clin Dermatol. 2003;4(6):371-8 Am J Clin Dermatol. 2001;2(3):143-50 J Dermatol Sci. 2005 Apr;38(1):1-7 Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):188-92. Effects of Topical DHEA on Aging Skin Dehydroepiandrosterone (DHEA) is a steroid hormone involved in physiological aging. When administered by oral route, it has been shown to positively affect the skin condition of aging people. The purpose of this pilot study, conducted in France, was to observe the in vivo effects on skin aging of topical DHEA (1%). The DHEA formulation (1%) or the vehicle was topically applied for 4 months to facial and hand skin, in two groups of 20 post-menopausal women. The efficacy of the treatment was evaluated on the basis of clinical and biophysical signs linked to skin aging. Results showed that DHEA treatment increased the rate of sebum production, which was perceived rather positively by a menopausal population usually affected with a declining sebum level. Topical DHEA tends to improve skin brightness, and to counteract papery appearance of skin and epidermal atrophy, a characteristic feature of hormone-related skin aging. Topical DHEA could also act on skin process related to wrinkles, but this result remains to be confirmed. In conclusion, this pilot study showed beneficial effects on skin characteristics that are rarely provided by topical treatments. Maturitas. 2008 Feb 20;59(2):174-81. Anti-Wrinkle Effect of Topical DMAE DMAE (2-dimethylaminoethanol, deanol) is an antioxidant found in abundance in fish, particularly salmon. Applied topically to the skin, DMAE may improve the appearance of sagging skin. DMAE boosts the effects of other antioxidants, increases smoothness, reduces fine lines and gives the facial muscles a leaner look. In a randomized clinical study, 3% DMAE facial gel applied daily for 16 weeks has been shown to be safe and efficacious in the mitigation of forehead lines and periorbital fine wrinkles, and in improving lip shape and fullness and the overall appearance of aging skin. These effects did not regress during a 2-week cessation of application. Beneficial trends were noted in the appearance of coarse wrinkles, under-eye dark circles, nasolabial folds, sagging neck skin, and neck firmness. Application was found to be well tolerated, with no differences in the incidence of erythema, peeling, dryness, itching, burning, or stinging between the DMAE and placebo groups. The cosmeceutical agent 2-dimethylaminoethanol (deanol; DMAE) is a tertiary amine found in high concentration in numerous topical antiwrinkle preparations. At the University of Quebec, Morissette et al. hypothesized that 3% DMAE applied to the skin could maintain a millimolar drug concentration within a certain depth of the skin layers, and that cell expansion could account for the very rapid effect on the apparent skin fullness. Br J Dermatol. 2007 Mar;156(3):433-9. Am J Clin Dermatol. 2005;6(1):39-47. Transdermal Delivery of Amino Acids and Antioxidants Enhances Collagen Synthesis One of the most visible changes associated with the aging process in humans relates to a progressive thinning of the skin. This results from a decline in both collagen and glycosaminoglycans, as well as from changes in their chemical structure and 3-dimentional organization. Transdermal administration of antioxidants, alpha-lipoic acid (ALA) 0.5% and proanthocyanidin (PA) 0.3% (a bioflavonoid found in grape seed extract) in a standard cosmetic vehicle base formulation supplemented with 2% benzyl alcohol as a penetration enhancer significantly enhanced collagen synthesis and deposition. Connect Tissue Res. 2005;46(4-5):251-7. ClearSpring Pharmacy specializes in bio-identical hormone therapy and customized antiaging preparations. © Storey Marketing. All rights reserved..
Load more

Recommended publications
  • Azelaic Acid
    Azelaic Acid (FINACEA) Topical Foam 15% National Drug Monograph August 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Azelaic acid is a naturally occurring C9-dicarboxylic acid that is found in plants Action (such as whole grain cereals), animals and humans. Azelaic acid has antiinflammatory, antioxidative and antikeratinizing effects. In rosacea skin, azelaic acid decreases cathelicidin levels and kallikrein 5 (KLK5) activity and possibly inhibits toll-like receptor 2 (TLR2) expression.1 A 15% gel formulation has been marketed for rosacea, and 20% cream has been available for acne vulgaris. The newer foam formulation consists of an oil- in-water emulsion and was designed to have a higher lipid content than the gel for dry and sensitive skin. Indication(s) Under Review Topical treatment of inflammatory papules and pustules of mild to moderate in This Document rosacea. Dosage Form(s) Under Foam, 15% Review REMS REMS No REMS Postmarketing Requirements See Other Considerations for additional REMS information Pregnancy Rating Category B Executive Summary Efficacy There have been no head-to-head trials comparing the foam and gel formulations of azelaic acid in terms of safety, tolerability and efficacy in the treatment of papulopustular (PP) rosacea.. In two major randomized clinical trials, azelaic acid foam produced small benefits over vehicle foam in achieving Investigator’s Global Assessment (IGA) treatment success (NNTs of 9.2 and 11.5) and in reducing inflammatory lesion counts.
    [Show full text]
  • VOLUME 7 2 . No. 4 . AUGUST 2 0
    VOLUME 72 . No.4 . AUGUST 2020 © 2020 EDIZIONI MINERVA MEDICA Minerva Pediatrica 2020 August;72(4):288-311 Online version at http://www.minervamedica.it DOI: 10.23736/S0026-4946.20.05861-2 REVIEW MANAGEMENT OF THE MAIN ENDOCRINE AND DIABETIC DISORDERS IN CHILDREN Current treatment for polycystic ovary syndrome: focus on adolescence Maria E. STREET 1 *, Francesca CIRILLO 1, Cecilia CATELLANI 1, 2, Marco DAURIZ 3, 4, Pietro LAZZERONI 1, Chiara SARTORI 1, Paolo MOGHETTI 4 1Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; 3Section of Endocrinology and Diabetes, Department of Internal Medicine, Bolzano General Hospital, Bolzano, Italy; 4Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy *Corresponding author: Maria E. Street, Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy. E-mail: [email protected] ABSTRACT Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women and it is associated with an in- creased rate of infertility. Its etiology remains largely unknown, although both genetic and environmental factors play a role. PCOS is characterized by insulin resistance, metabolic disorders and low-grade chronic inflammation. To date, the treatment of PCOS is mainly symptomatic and aimed at reducing clinical signs of hyperandrogenism (hirsutism and acne), at improving menstrual cyclicity and at favoring ovulation. Since PCOS pathophysiology is still largely unknown, the therapeutic interventions currently in place are rarely cause-specific.
    [Show full text]
  • 2021 SELECT EX FORMULARY the Following Is a List of the Most Commonly Prescribed Brand and Generic Medications
    2021 SELECT EX FORMULARY The following is a list of the most commonly prescribed brand and generic medications. It represents an abbreviated version of the formulary list that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. Some preferred medications overlap with other clinical programs and may not be covered. In addition to drugs on this list, the majority of generic medications are covered under your plan and you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. Search complete formulary drug information at elixirsolutions.com. PLEASE NOTE: Preferred brand drugs may move to non-preferred status if a generic version becomes available during the year. Any medication approved to enter the market will not be covered until reviewed by Elixir. Not all drugs listed are covered by all prescription drug benefit programs. For specific questions about your coverage, please visit elixirsolutions.com. A B CILOXAN OINTMENT digoxin abacavir tablet balsalazide CIMDUO diltiazem ER (except generics for abacavir-lamivudine BAQSIMI cinacalcet CARDIZEM LA) ABILIFY MAINTENA [INJ] BASAGLAR [INJ] ciprofloxacin dimethyl fumarate DR* abiraterone* BD ULTRAFINE INSULIN SYRINGES ciprofloxacin-dexamethasone diphenoxylate-atropine acetic acid & NEEDLES citalopram dipyridamole ER-aspirin acitretin BELBUCA CITRANATAL divalproex sodium ACUVAIL BELSOMRA clarithromycin divalproex sodium ER acyclovir capsule, tablet benzonatate (except NDCs: clarithromycin ER DIVIGEL
    [Show full text]
  • An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia Without Diabetes Joseph C
    Case Reports An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia without Diabetes Joseph C. Ratliff1 , Laura B. Palmese 1, Erin L. Reutenauer 1, Cenk Tek 1 Abstract A possible mechanism of antipsychotic-induced weight gain is activation of hypothalamic monophosphate-dependent kinase (AMPK) mediated by histamine 1 receptors. Alpha-lipoic acid (ALA), a potent antioxidant, counteracts this ef- fect and may be helpful in reducing weight for patients taking antipsychotics. The objective of this open-label study was to assess the efficacy of ALA (1,200 mg) on twelve non-diabetic schizophrenia patients over ten weeks. Participants lost significant weight during the intervention (-2.2 kg±2.5 kg). ALA was well tolerated and was particularly effective for individuals taking strongly antihistaminic antipsychotics (-2.9 kg±2.6 kg vs. -0.5 kg±1.0 kg). Clinical Trial Registra- tion: NCT01355952. Key Words: Schizophrenia, Obesity, Schizoaffective Disorder, Alpha-Lipoic Acid Introduction dependent protein kinase (AMPK) in the hypothalamus Antipsychotic medications appear to induce weight (4). In the periphery, AMPK increases energy utilization; gain, which results in increased rates of obesity in schizo- AMPK activity in the hypothalamus increases appetite. phrenia (1). Schizophrenia patients have significantly short- Several highly orexigenic (stimulates appetite) antipsy- er life expectancy than the general population (2); most of chotics such as clozapine, olanzapine, and quetiapine are this excess mortality is attributed to diabetes and cardiovas- shown to activate AMPK in the hypothalamus in animal cular disease (3); weight gain is a significant contributor to studies whereas other antipsychotic medications do not (4).
    [Show full text]
  • CVS Formulary Drug Listing
    January 2021 Updated 11/01/2020 Performance Drug List - Standard Control The CVS Caremark® Performance Drug List - Standard Control is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • The member's prescription benefit plan design may alter coverage this document. Products recently approved by the U.S. Food and of certain products or vary copay1 amounts based on the condition Drug Administration (FDA) may not be covered upon release being treated.
    [Show full text]
  • Supply Issues Update for Primary and Secondary Care: September 2019
    COMMERCIAL-SENSITIVE Supply Issues Update for Primary and Secondary Care: September 2019 This report has been produced by the Department of Health and Social Care (DHSC) Medicine Supply Team. We aim to update this report monthly to provide an update on current primary and secondary care medicine supply issues that we are working on. This information is confidential to the NHS; please do not upload to websites in the public domain. Please do share with relevant colleagues and networks. Where it has been stated ‘a clinical memo from UKMI will be published on the SPS website’, this will be found at the following URL: https://www.sps.nhs.uk/category/shortages-discontinuations-and-expiries/ Acetylcholine Chloride (Miochol-E) 20mg Contents powder and solvent for irrigation ..................8 New Issues ............................................................. 3 Aciclovir 500mg/1g injection .........................8 Injectables ......................................................... 3 Amikacin 500mg/2ml injection ......................8 Diamorphine 5mg injection ........................... 3 Emerade 500 microgram and 300 microgram Adrenaline 1 in 1000, 1ml ampoules ............. 4 adrenaline auto-injector (AAI) devices ..........8 Lanoxin (digoxin) 250mcg/ml injection ......... 4 EpiPen and EpiPen Junior ..............................9 Sayana Press (medroxyprogesterone acetate Erwinase injection ..........................................9 104mg) injection ............................................ 5 Haloperidol 5mg/ml injection ........................9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ Et Al
    US 2011 0236506A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ et al. (43) Pub. Date: Sep. 29, 2011 (54) PHARMACEUTICAL ASSOCIATION Publication Classification CONTAINING LIPOCACID AND (51) Int. Cl. HYDROXYCTRIC ACIDAS ACTIVE A633/24 (2006.01) INGREDIENTS A63L/385 (2006.01) A63/685 (2006.01) (75) Inventors: Laurent SCHWARTZ, Paris (FR): A63/4985 (2006.01) Adeline GUAIS-VERGNE, A63L/7056 (2006.01) Draveil (FR) A6IP35/00 (2006.01) (73) Assignees: Laurent SCHWARTZ, Paris (FR): (52) U.S. Cl. ........... 424/649; 514/440; 514/77: 514/249; BIOREBUS, Paris (FR) 514/52 (21) Appl. No.: 13/099,897 (57) ABSTRACT Pharmaceutical combination containing lipoic acid and (22) Filed: May 3, 2011 hydroxycitric acid as active ingredients. The present inven tion relates to a novel pharmaceutical combination and to the Related U.S. Application Data use thereof for producing a medicament having an antitumor (63) Continuation of application No. PCT/FR2009/ activity. According to the invention, this combination com 052110, filed on Nov. 2, 2009. prises, as active ingredients: lipoic acid or one of the pharma ceutically acceptable salts thereof, and hydroxycitric acid or (30) Foreign Application Priority Data one of the pharmaceutically acceptable salts thereof. Said active ingredients being formulated together or separately for Nov. 3, 2008 (FR) ....................................... O8574.48 a conjugated, simultaneous or separate use. Patent Application Publication Sep. 29, 2011 Sheet 1 of 9 US 2011/023650.6 A1 lipoic acid alone -29 f2 f Niger of ces i{t} v s 6 g i w 4. 6 8 i 2 Concentrations tumoi.i.
    [Show full text]
  • Philadelphia
    Saturday, April 18th, 2015 PCOS Awareness Symposium 2015 Philadelphia Polycystic Ovary Syndrome: Creating a Treatment Plan Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women’s Primary Care Thomas Jefferson University The Canary in the Coalmine . PCOS seems to accelerate the aging process . It is possible to reverse the aging process . Be scrupulous in your commitment to be healthy Multiple Systems . Reproductive . Endocrinologic . Cardiac . Renal (kidney) . Hepatic (liver) . Brain (mood) . Dermatologic Multiple Signs & Symptoms Irregular periods, Bleeding too much, Bleeding too little, Anxiety, Depression, Eating disorders, Weight gain, Acanthosis nigricans, Skin tags, Follicular keratitis, Hirsutism, Acne, Alopecia, Excess sweating, Seborrheic dermatitis, Hidradenitis supparativa, Fatty liver, High triglycerides, low HDL-cholesterol, Elevated glucose, Infertility, Breastfeeding problems, Poor sleep, Miscarriages, Fatigue, Endometrial cancer Multiple Pathways GnRH pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione & TGranulosa A* Estradiol X Follicle Peripheral conversion A* = aromatase More Pathways! GnRH Insulin pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione testosterone estradiol X ↓ SHBG Free T X Follicle Peripheral conversion The Magic Bullet The oral contraceptive pill . High doses of estrogen (ethinyl estradiol) . Increase SHBG and lower free testosterone* . Improve skin symptoms in most: . Alopecia .
    [Show full text]
  • Florida Medicaid Brand Drug Preferred List*
    FLORIDA MEDICAID BRAND DRUG PREFERRED LIST* Brand Name Generic Name Advair Diskus for inhalation fluticasone/salmeterol diskus Aggrenox capsules aspirin/dipyridamole Albenza tablets albendazole Androgel gel pack/pump** testosterone Avelox tablets** moxifloxacin Azactam vials aztreonam Benicar/Benicar-HCT tablets** olmesartan/olmesartan-HCTZ Bicnu vials carmustine Biltricide tablets praziquantel Butrans patch** buprenorphine transdermal Catapres TTS patch clonidine patch ER Cellcept suspension mycophenolate mofetil Cipro suspension (250mg/5ml & 500mg/5ml) ciprofloxacin Copaxone syringes 20mg glatiramer accetate/Glatopa Derma-Smoothe-FS oil fluocinolone 0.01% oil Differin cream and lotion adapalene erythromycin ethylsuccinate E.E.S. 200mg/5ml suspension - New addition suspension Elidel 1% cream pimecrolimus Emend capsules aprepitant Exelon patch rivastigmine transdermal Finacea GEL 15% azelaic acid Focalin XR capsules dexmethylphenidate hcl Gleevec tablets imatinib Mesylate Glyset tablets miglitol Humalog vial insulin lispro vial Kitabis Pak tobramycin pak Lamictal Dose Pak lamotrigine dose pak Lescol capsules / Lescol XL tablets** fluvastatin ER Letairis tablets** ambrisentan Lialda 1.2g tablets** mesalamine 1.2 g Lotemax 0.5% drops - New addition loteprednol 0.5% drops Makena single dose vial & auto inj** hydroxyprogesterone caproate vial Mephyton tablets phytonadione tablets Micardis and Micardis HCT tablets** telmisartan and telmisartan HCT Natroba suspension spinosad Norvir tablets ritonavir tablets Prevacid ODT lansoprazole ODT Proair
    [Show full text]
  • Antiwrinkle Creams: a Comparative Study of Efficacy Between a New Antiaging Proprietary Formulation and a Market Leader Amy B
    STUDY Antiwrinkle Creams: A Comparative Study of Efficacy Between a New Antiaging Proprietary Formulation and a Market Leader Amy B. Lewis, MD This comparative, double-blinded study included 62 subjects and assessed the efficacy and tolerance of 2 antiwrinkle facial creams: Alyria Intense Wrinkle Correction/Wrinkle Repair and StriVectin-SD®, a popular product currently on the market. Volunteers applied the products twice daily during a period of 3 months. While bothCOS treatments were well DERM tolerated and well perceived by the majority of subjects, clear differences were observed in the results. The improvements achieved with Alyria Intense Wrinkle Correction/Wrinkle Repair appeared more significant than those achieved with StriVectin-SD, primarily in the number of wrinkles, the appearance of deeper wrinkles, and the surface area and total length of wrinkles. Do Not Copy ging is inevitable. However, when it comes with intact elastic fibers that yields tensile strength, elas- to the visible signs of aging on the skin, ticity, and resilience.1 The high concentration of glycos- what used to be unavoidable may not be aminoglycans, especially hyaluronic acid, provides the so anymore. There are 2 different catego- skin with ample hydration.2 Intrinsic aging begins when ries of skin aging: intrinsic and extrinsic.1 people are in their twenties, even though the signs may AIntrinsic aging comes from within, the result of natural not be visible for decades. Reduced collagen production changes caused by hormones, genetic factors, chronic causes dermal atrophy (eg, fine wrinkles, thinner skin), muscle tension, and gravity. In the extracellular matrix of and decreased concentration of glycosaminoglycans leads newborn skin, there is an abundant collagen meshwork to loss of hydration (dry skin) and slower turnover of dead skin cells (coarse texture).2,3 Reduced elastic fibers Dr.
    [Show full text]
  • Mitochondrial Dysfunction and Chronic Inflammation in Polycystic
    International Journal of Molecular Sciences Review Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome Siarhei A. Dabravolski 1,*, Nikita G. Nikiforov 2,3,4, Ali H. Eid 5,6,7, Ludmila V. Nedosugova 8, Antonina V. Starodubova 9,10, Tatyana V. Popkova 11, Evgeny E. Bezsonov 4,12 and Alexander N. Orekhov 4 1 Department of Clinical Diagnostics, Vitebsk State Academy of Veterinary Medicine [UO VGAVM], 7/11 Dovatora Str., 210026 Vitebsk, Belarus 2 Center of Collective Usage, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilova Street, 119334 Moscow, Russia; [email protected] 3 Laboratory of Medical Genetics, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, 121552 Moscow, Russia 4 Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Institute of Human Morphology, 3 Tsyurupa Street, 117418 Moscow, Russia; [email protected] (E.E.B.); [email protected] (A.N.O.) 5 Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha 2713, Qatar; [email protected] 6 Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha 2713, Qatar 7 Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon 8 Citation: Dabravolski, S.A.; Federal State Autonomous Educational Institution of Higher Education, I. M. Sechenov First Moscow State Nikiforov, N.G.; Eid, A.H.; Medical University (Sechenov University), 8/2 Trubenskaya Street, 119991 Moscow, Russia; [email protected] 9 Federal Research Centre for Nutrition, Biotechnology and Food Safety, 2/14 Ustinsky Passage, Nedosugova, L.V.; Starodubova, A.V.; 109240 Moscow, Russia; [email protected] Popkova, T.V.; Bezsonov, E.E.; 10 Pirogov Russian National Research Medical University, 1 Ostrovitianov Street, 117997 Moscow, Russia Orekhov, A.N.
    [Show full text]
  • Safety of Alpha-Lipoic Acid Use in Food Supplements
    DTU Doc nr. 17/14450 Date 10.10.2017 Safety of alpha-lipoic acid use in food supplements The Danish Veterinary and Food Administration has asked DTU FOOD to assess the safety of alpha-lipoic acid use in food supplements in a recommended daily dose of 150-200 mg per day. Specification for alpha-lipoic acid SYNONYMS Thioctic acid 1,2-dithiolane-3-pentanoic acid; 1,2-dithiolane-3-valeric acid DEFINITION Chemical name 1,2-Dithiolan-3-pentanic acid CAS Number 1077-28-7 Chemical formula Molecular formula C8H14O2S2 Molecular weight 206.32 g/mol Content Not less than 99.0% and no more than 101.0% alpha-lipoic acid determined by gas chromatography IDENTIFICATION Identification test IR absorption. The spectrum should be in accordance with an equivalent reference spectrum 60-62° C A. Melting point 22 ° B. Specific rotation [α]D : +/- 1.0 (50 mg/ml in ethanol) PURITY Loss on drying No more than 0,2% Ashes No more than 0.1% Heavy metals No more than 10 mg/kg (by method II, Ph. US 39., 673. Mercury is not identified by this test) Lead Not more than 1 mg/kg Specification in accordance with the United States Pharmacopeia (USP) Studies in humans No studies on alpha-lipoic acid conducted in healthy subjects were identified in the literature. Healthy subjects are the target group for food supplements. Several studies conducted in different patient groups including patients with diabetic neuropathy, infertile men, overweight or obese hypertensive, diabetic or hypercholesterolemic subjects were identified (Han et al., 2012; Koh et al., 2011 ; Hahm et al., 2004; Technical University of Denmark Kemitorvet Ph.
    [Show full text]